01:05 PM EDT, 03/11/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our target price on shares of Boston Scientific ( BSX ) to $75 from $71, 29.3x our 2025 EPS estimate, a premium to BSX's historical forward average, justified by our expectations for superior growth compared to its peers. We maintain our 2024 EPS estimate at $2.27 and 2025's at $2.56. We think BSX shares are slightly under pressure since Friday driven by concerns that the Federal Trade Commission (FTC) may be investigating the $3.7B Axonics, Inc. deal announced in January due to the two companies' key market positions in urinary incontinence therapies. We see the proposed transaction as a clear positive for BSX to further grow in its MedSurg segment, particularly in urology. The company initially expected the deal to be completed in the first half of 2024, but it may see some potential delays, in our view, due to the FTC scrutiny. Yet, absent the additional contributions from Axionics, we continue to see BSX as attractively positioned for healthy growth during 2024.